Matthew Dyer
About Matthew Dyer
Matthew Dyer is the Director of Worldwide HEOR Markets - Oncology at Bristol Myers Squibb, with over 15 years of experience in health economics and outcomes research.
Current Role at Bristol Myers Squibb
Matthew Dyer is currently serving as the Director, Worldwide HEOR Markets - Oncology at Bristol Myers Squibb. In this role, he contributes to the development of health economic strategies for oncology treatments. His experience and expertise in the field of health economics and outcomes research are crucial in shaping policies and strategies within the oncology division.
Previous Experience at AstraZeneca
Prior to his current position, Matthew Dyer worked at AstraZeneca for eight years. From 2017 to 2021, he held the role of Director, Health Economics & Payer Analytics, where he led initiatives in Cambridge, United Kingdom. Before this, he was a Health Economist at AstraZeneca from 2013 to 2017, where he honed his skills in health economics modeling and payer analytics.
Years in Health Economics and Outcomes Research
Matthew Dyer has accumulated over 15 years of experience in the field of health economics and outcomes research (HEOR). His work spans various roles and responsibilities, including positions at the National Institute for Health and Clinical Excellence, Creativ-Ceutical, and The Royal College of Psychiatrists. This extensive experience has enabled him to influence healthcare policy decisions significantly.
Research and Publications
Throughout his career, Matthew Dyer has participated in numerous international conferences on health economics and outcomes research. He has also published several research papers in peer-reviewed journals, contributing valuable insights to the field of health economics. His work continues to be recognized and referenced within academic and professional circles.
Collaborations and Leadership
In addition to his technical expertise, Matthew Dyer is known for his leadership qualities. He has successfully led cross-functional teams in the pharmaceutical industry and has a track record of collaborations with healthcare institutions and regulatory bodies. His ability to work well with various stakeholders underlines his effectiveness in implementing health economic strategies.